Treating anemia in CKD and ESRD often requires Epogen. Many of such patients are diabetic that monitor their Hgb-A1C.
What is the effect of anemia management in this patient population on A1C levels??
Erythropoietin offers renoprotective effects. When erythropoietin is administered to CKD patients especially those associated with diabetes, the erythropoietin will heal improve the renal function by affecting the fibroblasts which will increase the level of haemoglobin and then ensure the normalising Hgb-A1C.
Since erythropoietin stimulates erythrocytes production and HGB, it can affect HGB A1C percentage which is the market of sugar control.
With uremia we know the lifespan erythrocytes is shortened. As so and with starting erythropoietin we expect that the newly generated erythrocytes (young RBC) will not have time enough to be glycosylated even with high glycemic environment. In conclusion, EPO usage will have HbA1c underestimating the glycemic values and overestimating diabetes control. A good alternative seems to be glycated albumin.
Kind regards,
Fernando Pereira
I agree with the answer of Dr Pereira.In this case as a biomarkers of glycemic control must be used glycated albumin,fructosamine or 1,5 aminoglucytol
Best regards
- Badges
- Science topic
- Similar topics
- Medicine
- Disease
- Metabolic Diseases
- Glucose Metabolism Disorders
- Diabetes